AURX 8-K: SEC filing

Nuo Therapeutics, Inc.

Filed with the SEC on · accession 0001437749-26-037320

AURX filed a 8-K (current report) with the SEC on Nov 17, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Nuo Therapeutics, Inc. issued a press release announcing its financial results for the third quarter and first nine months of 2026, furnished as Exhibit 99 under Item 2.02 of Form 8-K.

Key details

RegistrantNuo Therapeutics, Inc.
Chief executive and chief financial officerDavid E. Jorden

✦ Ask GOAX AI about this filing — what it means for AURX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for AURX?

Click here

Frequently asked questions

What did AURX file with the SEC on Nov 17, 2026?

AURX filed a 8-K (SEC filing). Nuo Therapeutics, Inc. issued a press release announcing its financial results for the third quarter and first nine months of 2026, furnished as Exhibit 99 under Item 2.02 of Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other AURX SEC filings

Get alerts when AURX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days